Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Genetics and anatomy sculpt immune-cell partners of ovarian cancer

The therapeutic options available to treat ovarian cancer need improvement. Data that reveal the cellular, molecular and mutational landscape as such tumours grow and spread might aid efforts to develop new targeted therapies.
  1. Denarda Dangaj Laniti

    1. Denarda Dangaj Laniti is at the Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, Lausanne University Hospital and University of Lausanne, Agora Cancer Research Center, Lausanne 1011, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. George Coukos

    1. George Coukos is at the Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, Lausanne University Hospital and University of Lausanne, Agora Cancer Research Center, Lausanne 1011, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

The most common type of ovarian cancer1, called high-grade serous ovarian cancer (HGSOC), is challenging from a therapeutic perspective. By the time most individuals are diagnosed with this type of tumour, it has already spread (metastasized) from the primary site to distant regions, seeding cancer cells in multiple abdominal locations (intraperitoneal sites). At that point, symptoms arise because of an accumulation of peritoneal fluid in these areas. Writing in Nature, Vázquez-García et al.2 provide insights into metastatic ovarian cancer.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 612, 634-636 (2022)

doi: https://doi.org/10.1038/d41586-022-04169-3

References

  1. Kurman, R. J. Ann. Oncol. 24, x16–x21 (2013).

    Article  PubMed  Google Scholar 

  2. Vázquez-García, I. et al. Nature 612, 778–786 (2022).

    Article  Google Scholar 

  3. The Cancer Genome Atlas Research Network. Nature 474, 609–615 (2011).

    Article  PubMed  Google Scholar 

  4. Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Nature Rev. Cancer 22, 640–656 (2022).

    Article  PubMed  Google Scholar 

  5. McPherson, A. et al. Nature Genet. 48, 758–767 (2016).

    Article  PubMed  Google Scholar 

  6. Zhang, A. W. et al. Cell 173, 1755–1769 (2018).

    Article  PubMed  Google Scholar 

  7. Bruand, M. et al. Cell Rep. 36, 109412 (2021).

    Article  PubMed  Google Scholar 

  8. Zhang, L. et al. N. Engl. J. Med. 348, 203–213 (2003).

    Article  PubMed  Google Scholar 

  9. Dangaj, D. et al. Cancer Cell 35, 885–900 (2019).

    Article  PubMed  Google Scholar 

  10. Duraiswamy, J. et al. Cancer Cell 39, 1623–1642 (2021).

    Article  PubMed  Google Scholar 

  11. Ding, L. et al. Cell Rep. 25, 2972–2980 (2018).

    Article  PubMed  Google Scholar 

  12. Peng, D. et al. Nature 527, 249–253 (2015).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

G.C. has received grants, research support or is co-investigator in clinical trials by Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. G.C. has patents in the domain of antibodies and vaccines targeting the tumour vasculature, as well as technologies related to T-cell expansion and engineering for T-cell therapy.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links